GlassScriptPhysician profile
Heather L Lappin
NPI 1265877427
$3,876.69
in general payments reported to CMS, 2019-2025
25 companies · $851 in 2025
The $851 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $478 · 2022: $616 · 2023: $899 · 2024: $1,033 · 2025: $851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,676 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,676.06 |
| Education | $106.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,445.01 | 2021-2025 | |
| Janssen Biotech, INC. | $345.04 | 2021-2025 | Stelara, Tremfya, Remicade |
| Ipsen Biopharmaceuticals, INC | $271.44 | 2024-2025 | Iqirvo |
| Takeda Pharmaceuticals U.S.A., INC. | $249.22 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $206.46 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $173.17 | 2023-2025 | Terlivaz |
| Regeneron Healthcare Solutions, INC. | $155.49 | 2024-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.74 | 2021-2025 | Xifaxan, Trulance |
| Genzyme Corporation | $137.95 | 2022-2025 | |
| Lilly USA, LLC | $116.25 | 2024-2025 | Omvoh |
| Celgene Corporation | $109.51 | 2022-2024 | Zeposia |
| Gilead Sciences, INC. | $107.42 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $72.96 | 2022 | |
| Qol Medical, LLC | $71.76 | 2022-2024 | Sucraid |
| Ucb, INC. | $52.51 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $46.47 | 2025 | Zenpep |
| Ardelyx, INC. | $30.85 | 2022-2023 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $28.60 | 2023-2025 | Ocaliva |
| Merck Sharp & Dohme LLC | $19.58 | 2023 | Dificid |
| Organon LLC | $17.04 | 2024-2025 | Hadlima, Renflexis |
| Madrigal Pharmaceuticals | $14.73 | 2025 | Rezdiffra |
| Celltrion USA INC. | $14.42 | 2025 | Vegzelma |
| Fresenius Kabi USA, LLC | $13.38 | 2023 | Smoflipid |
| Ironwood Pharmaceuticals, INC | $12.50 | 2022 | |
| Braintree Laboratories, INC. | $11.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Lappin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.